ERBB2 and breast carcinoma: MUC1 with excessive O-glycosylation also increased the expression of MDR proteins and ultimately attenuated the sensitivity of HER2+ and/or ER+ breast cancer cells to bortezomib, trastuzumab, and tamoxifen [212].